Within the living ecosystem of the human gut, scientists at Duke University have discovered that ancient bacterial proteins are not silent passengers but active messengers, speaking directly to the brain through a network of specialized nerve cells and the vagus nerve. A protein called flagellin, found on the tails of common gut bacteria, triggers a fullness signal that travels upward to suppress appetite — a biological conversation that has been happening inside us long before we had words for hunger. Published in Nature, the research reframes digestion itself as something closer to a sensory
Scientists identify 'sixth sense' in gut bacteria that signals brain to stop eating
Cobertura Relacionada
Australian model Leah Ramsey lost her baby after a small foot cut triggered a rare heart infection that was repeatedly m…
Informanté · Aug 23 South Africa Shares FMD Vaccines as Region Strengthens Disease ControlsSouth Africa reports its largest-ever FMD outbreak is coming under control through accelerated vaccination and regional …
Al Jazeera · Aug 23 Solar telemedicine kiosks expand healthcare access across rural ChadSolar-powered telemedicine kiosks in rural Chad enable remote doctor consultations at a fraction of traditional travel c…
Inquirer.net · Aug 23 Prince Harry returns to UK amid family rifts, seeking reconciliation with monarchyPrince Harry and Meghan Markle are relocating back to Britain after six years in California, potentially signaling recon…
Viés e Enquadramento
Não há dados de análise detalhada para esta lente. Tente executar as lentes novamente no painel de administração.
Impacto Geopolítico
Duke University's discovery of gut bacteria signaling fullness to the brain has no direct geopolitical implications; it is a biomedical advancement with potential health applications.
Lente Econômica
Discovery of gut bacteria's appetite-suppressing signaling mechanism could revolutionize obesity treatment and create new pharmaceutical markets for gut-brain therapeutics.
Consumers may benefit from new obesity and mental health treatments, potentially reducing healthcare costs. However, this could disrupt the diet industry and weight-loss supplement markets. Food companies may need to reformulate products to support healthy gut bacteria.
Regulatory agencies (FDA, EMA) will need to establish frameworks for approving microbiome-based therapeutics. Potential subsidies for probiotic foods or treatments. Public health policies may shift toward gut health education. Insurance coverage decisions for new gut-brain therapies will emerge.